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Abstract
Management of adults with failing Fontan physiology poses many challenges, especially as transplantation offers the only re-
alistic alternative to palliative care. We present the ﬁrst combined heart and liver transplant performed in Europe, for a late
survivor of single ventricle palliation with the Fontan circulation. In addition to the conventional medical and surgical chal-
lenges posed, we highlight the management of the associated multi-organ failure with focus on the liver and novel strategies
for assessment and optimization.
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Introduction
Since 1971, Fontan surgery has transformed the outlook for
single ventricle patients.1 This affects around 16 per
100 000 children with most now surviving to adulthood.2
The circulation depends on low pulmonary vascular resis-
tance facilitating adequate preload to the systemic ventricle.3
However, even the well-functioning circuit eventually fails as
chronic non-pulsatile pulmonary ﬂow and elevated systemic
venous pressures accelerate multi-organ failure. Manage-
ment of the failing Fontan is not limited to replacing the
pump but also addressing the extra-cardiac problems associ-
ated with the declining circulation.
Transplantation, at present, provides the only alternative to
palliative care but has high early mortality and poorly deﬁned
referral criteria. The present case highlights the complexity of
the situation, particularly with respect to liver involvement.
Case report
A 50-year-old man with small tricuspid valve, hypoplastic
double-outlet right ventricle, peri-membranous ventricular
septal defect, and malposed great vessels underwent a mod-
iﬁed atriopulmonary Fontan (homograft valves at right atrial
junction with caval veins and pulmonary artery) at 9 years
old.4 He remained well, working full-time, until his 30s, when
he developed arrhythmia. In his late 40s, he began to experi-
ence exertional symptoms and abdominal swelling because
of ascites.
Cardiovascular magnetic resonance (CMR) showed a large
(90 × 74 mm) right atrium, no atrioventricular valve regurgi-
tation or Fontan pathway narrowing, and preserved systolic
ventricular function (ejection fraction 59%). Mean right atrial
pressure was 22 mmHg. He had marked thoracic veno-
venous collaterals, amiodarone-associated thyroid disease,
iron deﬁciency, and impaired renal function (creatinine
266 μmol/L).
Despite preserved synthetic liver function (bilirubin
14 μmol/L, albumin 46 g/L), computerized tomography
showed cirrhosis and portal hypertension (recanalized umbil-
ical vein and splenomegaly). Novel CMR sequences5 opti-
mized for high resolution cardiac ﬁbrosis detection
highlighted coarse nodular liver architecture implying exten-
sive ﬁbrotic change (Figure 1A and B). There were no liver re-
generative nodules. Child Pugh score was 7, Childs grade B,
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MELD-XI 24, and VAST 3. Progressive liver disease and risk of
hepatic decompensation justiﬁed combined listing for heart
and liver transplantation.
The patient was admitted for diuresis, milrinone infusion,
and serial abdominal paracentesis to optimize
haemodynamics and end-organ function. This was compli-
cated by two episodes of sepsis (secondary to an ascitic tap
and an intravenous cannula). Between admission and trans-
plantation (7 months), 6–10 L of ascites was removed bi-
weekly, creatinine improved from 292 to 130 μmol/L, and bil-
irubin from 19 to 10 μmol/L. At transplantation, MELD-XI
score was 11.
Operative course
The organs were procured from a single donor following
donor–recipient crossmatch. The patient had been prioritized
locally for a matched block. Heart transplant was performed
via redo-median sternotomy with bicaval cannulation and
the abdomen closed. Caval vein and pulmonary artery anas-
tomoses were completed with the aortic clamp removed,
and the heart was reperfused. After weaning bypass, the
chest was left open, and liver transplant was performed using
standard caval replacement technique. The allograft ischae-
mic time was 147 min. The whole operation was performed
on cardio-pulmonary bypass with a bypass time of 727 min
and a total operative time of 1102 min.
Liver histopathology
The explanted liver weighed 1.58 kg and was irregular with
multiple tan nodules (1 to 5 mm) (Figure 1C). Histology, con-
sistent with CMR, showed extensive broad sclerotic ﬁbrous
bands surrounding small nodules (Figure 1D). There was
marked sinusoidal dilatation, signiﬁcant atrophy, and focal
parenchymal necrosis. The portal vein showed muscular hy-
pertrophy and intimal thickening consistent with portal
hypertension.
Immunosuppression and monitoring
Methylprednisolone 10 mg/kg was administered at anaes-
thetic induction and tapered off over months to a mainte-
nance dose. Basiliximab and ciclosporin A were given on
Day 1 but replaced with Tacrolimus on Day 2; this was
switched back to ciclosporin A on Day 87 because of clinical
neurotoxicity. Mycophenolate mofetil was given for a short
period at 3 months because of ﬂuctuating ciclosporin levels
but discontinued because of concomitant confusion.
Figure 1 (A) and (B) Coarse, nodular, and ﬁbrotic appearance of liver late after gadolinium contrast injection. (C) Gross appearance of explanted liver.
(D) Histology (collagen stain) showing dense collagenous septa. Artefacts: Asterisk indicates inferior vena caval metallic stent artefact in (A) and the
triangles indicate respiratory navigator cross bars in (B).
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Rejection was assessed by echocardiography and hepatic
biochemical function. Endomyocardial biopsies performed at
3, 5, and 7 weeks and 3, 4, and 6 months showed no evidence
of rejection. Augmentation (three doses of methylpredniso-
lone 10 mg/kg) was given for clinical liver rejection on Day
4. Liver biopsy at 2 weeks showed cholestasis and possible
features of sepsis or drug-induced liver injury but no acute re-
jection. Liver biopsy at 4 months showed moderate–severe
acute rejection, and augmentation was repeated.
Post-operative recovery
The length of stay on intensive care was 57 days with four
readmissions for sepsis, graft rejection, and tacrolimus neuro-
toxicity. Morbidity is shown in the Table 1. The patient re-
quired continuous haemoﬁltration for 1 month, and then,
variable periods of intermittent haemodialysis ﬁnally
discontinued at 7 months. Notably, he had persistent right
pleural effusion, ascites (drained twice), and peripheral oe-
dema for several months following transplantation. The total
length of stay was 14 months (7 months post-transplant). Dis-
charge creatinine was 180 μmol/L. Following discharge, the
patient enrolled in intensive rehabilitation and returned to
full-time work. He is presently New York Heart Association
functional class I with good cardiac function on echo, normal
liver function, and moderate renal impairment managed
without dialysis.
Discussion
The adult Fontan population is rapidly expanding, and this
case is signiﬁcant for physicians counselling these patients
and planning future care. To our knowledge, our patient is
the ﬁrst in Europe to undergo combined heart and liver trans-
plant (CHLT) for advanced failing Fontan physiology. Recently,
CHLT in this setting has been reported in the USA with good
outcomes; it should be noted that our patient, in comparison,
was older and at the advanced end of the Fontan failure spec-
trum with renal dysfunction, portal hypertension, and signif-
icant chest wall collaterals.6 Though feasible, the approach
demands huge investment from the patient, their family,
and health professionals.
Isolated heart transplantation in the failing Fontan is com-
plicated by anatomical complexity, potentially high levels of
preformed human leucocyte antibodies, susceptibility to in-
fection, and high risk of bleeding or multi-organ failure.7
The degree of hepatic and renal impairment needs case-by-
case assessment by a multi-disciplinary team, as multi-organ
transplantation may be required. While cirrhosis adversely af-
fects outcome following cardiac surgery, it is not known at
what point liver dysfunction may preclude isolated cardiac
transplantation in this group.8
The spectrum of liver disease is wide and presently unpre-
dictable and includes hyper-vascular nodules, hepato-cellular
carcinoma, portal hypertension, and ascites. Liver synthetic
function is often preserved despite signiﬁcant reduction in
liver volume and/or extensive ﬁbrosis on histology. In our
case, non-invasive CMR tissue characterization suggested ex-
tensive scarring of the liver. Extending the ﬁeld of view of
novel ﬁbrosis sequences to intentionally include the liver
alongside the heart may offer earlier detection of disease
progression. This however requires further evaluation. At
present, our practice is that patients with cirrhosis but with
normal synthetic function, normal hepatic venous anatomy,
good liver volume, and no signiﬁcant portal hypertension or
hepato-cellular carcinoma may be considered for heart-only
transplantation.
The CHLT is suggested to have an immuno-protective ef-
fect attributed to the transplanted liver, and long-term out-
comes in congenital patients are favourable.9,10 In the
recent CHLT series in Fontan patients, indicated for cirrhosis,
1 year survival was 100% in contrast to around 65% reported
for heart alone transplant in a similar group.6,7 There is,
Table 1 Post-transplantation morbidity
System Event Post-operative day
Respiratory Tracheostomy (failed extubation ×2) Day 12
Hospital acquired pneumonia Day 111a
Persistent right pleural effusion
Sepsis Gangrenous umbilicus debrided Day 8
Percutaneous drainage of abdominal abscess Day 29
Mediastinitis debrided Day 48a
Liver Infarcted one segment of graft
Biliary anastomotic leak: stented via ERCP Day 32
Renal Continuous renal replacement therapy 4 weeks
Variable periods of intermittent renal replacement therapy 6 months
Neurological Presumed neurotoxicity from Tacrolimus Day 87a
Gut and nutrition Nasogastric and jejunal feeding/total parental nutrition 2 months
Persistent ascites
ERCP, endoscopic retrograde cholangiopancreatogram.
aDenotes event necessitating readmission to intensive care.
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however, a recognized shortage of organ donors. Concerns
may reasonably be raised regarding the advisability of utiliz-
ing two organs in a high-risk complicated transplant when pa-
tients with more straightforward anatomy requiring single
organs are potentially dying on the waiting list. The
prolonged waiting time can be utilized, however, to optimize
end-organ function prior to transplantation, and we have
found this strategy, reported elsewhere, to be effective in
the Fontan setting.11 Nevertheless, this may be complicated
by hospital-acquired infection and prolongation of stay. Ex-
pectant anaesthetic management of complex perioperative
issues, including haemorrhage and coagulaopathy, may also
help support good outcomes.12
Our case highlights the emerging problem of liver dysfunc-
tion in the older Fontan patient. It demonstrates that al-
though a good outcome from multi-organ transplantation
can be obtained, resource implications are such that this
treatment can only be relied on for a few. Other strategies,
including novel diagnostic and therapeutic approaches, will
need to be developed and validated.
Conﬂict of interest
None declared.
References
1. Fontan F, Mounicot FB, Baudet E,
Simonneau J, Gordo J, Gouffrant JM.
“Correction” of tricuspid atresia. 2 cases
“corrected” using a new surgical tech-
nique. Ann Chir Thorac Cardiovasc
1971; 10: 39–47.
2. Coats L, O’Connor S, Wren C, O’Sullivan
JJ. The single-ventricle patient popula-
tion: a current and future concern a
population-based study in the North
of England. Heart 2014; 100:
1348–1353.
3. Gewillig M, Brown SC. The Fontan circu-
lation after 45 years: update in physiol-
ogy. Heart 2016; 102: 1081–1086.
4. Yacoub MH, Radley-Smith R. Use of a
valved conduit from right atrium to pul-
monary artery for “correction” of single
ventricle. Circulation 1976; 54(6 Suppl):
1163–1170.
5. Keegan J, Jhooti P, Babu-Narayan SV,
Drivas P, Ernst S, Firmin DN. Improved
respiratory efﬁciency of 3D late gadolin-
ium enhancement imaging using the
continuously adaptive windowing strat-
egy (CLAWS). Magn Reson Med 2014;
71: 1064–1074.
6. D’Souza BA, Fuller S, Gleason LP,
Hornsby N, Wald J, Krok K, Shaked A,
Goldberg LR, Pochettino A, Olthoff KM,
Kim YY. Single center outcomes of com-
bined heart and liver transplantation in
the failing Fontan. Clin Transplant
2017; 31.
7. Murtuza B, Hermuzi A, Crossland DS,
Parry G, Lord S, Hudson M, Chaudhari
MP, Haynes S, O’Sullivan JJ, Hasan A.
Impact of mode of failure and end-
organ dysfunction on the survival of
adult Fontan patients undergoing car-
diac transplantation. Eur J Cardiothorac
Surg 2017; 51: 135–141.
8. Hsieh WC, Chen PC, Corciova FC, Tinica
G. Liver dysfunction as an important
predicting risk factor in patients under-
going cardiac surgery: a systematic re-
view and meta-analysis. Int J Clin Exp
Med 2015; 8: 20712–20721.
9. Pinderski LJ, Kirklin JK, McGifﬁn D et al.
Multi-organ transplantation: is there a
protective effect against acute and
chronic rejection? J Heart Lung Trans-
plant 2005; 24: 1828–1833.
10. Bradley EA, Pinyoluksana KO, Moore-
Clingenpeel M, Miao Y, Daniels C. Iso-
lated heart transplant and combined
heart-liver transplant in adult congenital
heart disease patients: insights from the
United Network of Organ Sharing. Int J
Cardiol 2017; 228: 790–795.
11. Stevenson LW. Clinical use of inotropic
therapy for heart failure: looking back-
ward or forward? Part II: chronic inotro-
pic therapy. Circulation 2003; 108:
492–497.
12. Navaratnam M, Ng A, Williams GD,
Maeda K, Mendoza JM, Concepcion W,
Hollander SA, Ramamoorthy C. Periop-
erative management of pediatric en-
bloc combined heart-liver transplants: a
case series review. Paediatr Anaesth
2016; 26: 976–986.
678 P. Duong et al.
ESC Heart Failure 2017; 4: 675–678
DOI: 10.1002/ehf2.12202
